Sarepta Therapeutics | SRPT - Current Assets


Sarepta Therapeutics reported $2.31B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
Agios Pharmaceuticals USD 834.84M 107.21M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
BioCryst Pharmaceuticals USD 373.62M 30.72M Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Capricor Therapeutics USD 283.09M 39.85M Mar/2026
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Eli Lilly USD 54.84B 794M Mar/2026
Esperion Therapeutics USD 459.46M 3.11M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Moderna USD 5.77B 774M Mar/2026
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Novavax USD 850.82M 127.46M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Regeneron Pharmaceuticals USD 18.21B 187.3M Mar/2026
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sanofi EUR 30.16B 789M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Tectonic Therapeutic USD 239.89M 17.47M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026